IDEXX Laboratories, Inc.

“IDEXX is among the best-quality businesses available to public market investors — a structurally dominant, capital-light compounder with 30-55% ROIC, widening moat, and a genuine decade-plus reinvestment runway in underpenetrated global vet diagnostics; however, at 33x forward P/E after a 29% pullback, the valuation still embeds most of the upside, capping 10-year expected returns to roughly 6-9% CAGR and offering insufficient margin of safety for a new position — the right action is to track closely and initiate if the stock reaches 27-28x forward earnings (~$450-480).”